Igor Aurer

10PUBLICATIONS
58CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Cancer geneticsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 29, 2025
Efficacy, Toxicity and Effect of Pretreatment Cardiologic Consultation on Outcomes of Ibrutinib Therapy for Chronic Lymphocytic Leukemia-A KroHem Study.

Inga Mandac Smoljanović, Igor Aurer, Nikola Bulj

|Jun 17, 2025
COVID-19 burden of illness in people who are immunocompromised due to cancer: an expert opinion review.

Igor Aurer, Paul Moss, Michel Goldman

|Jan 08, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.

Elizabeth H Phillips, Nicholas Counsell, Tim Illidge

|Jan 08, 2025
Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases.

Igor Aurer, Ozren Jakšić, Sandra Bašić-Kinda

|Dec 16, 2024
Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals.

Christoph D Spinner, Samira Bell, Hermann Einsele

|Feb 24, 2024
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era-A Study of KroHem, the Croatian Group for Hematologic Diseases.

Igor Aurer, Ozren Jakšić, Sandra Bašić-Kinda

Pageof 2

Frequent Collaborators

2 joint publications

Mats Jerkeman

2 joint publications

Davor Galusic

2 joint publications

Gkikas Magiorkinis

2 joint publications

Ozren Jaksic